Non-Small Cell Lung Cancer Coverage from Every Angle

ESMO 2020: Vinorelbine Plus Atezolizumab in Recurrent Stage IV Lung Cancer

By: Lauren Harrison, MS
Posted: Tuesday, October 13, 2020

Dual therapy using metronomic oral vinorelbine and atezolizumab in the treatment of recurrent stage IV non–small cell lung cancer (NSCLC) may be achieved without significant toxicity. Metronomic oral vinorelbine is a low-dose and frequent chemotherapy. Alain Vergnenegre, MD, PhD, of the University of Limoges, France, presented details from this study on behalf of his colleagues at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 (Abstract 1310P).

This multicenter, single-arm, phase II trial consisted of two phases. In the first phase, patients with NSCLC who had relapsed after platinum-based therapy were recruited to receive 40 mg of vinorelbine three times a week and atezolizumab. This phase included 12 patients and was aimed at ensuring the safety of fixed dosing of atezolizumab.

The second phase of the trial included 80 patients who received the same medication dosing as in the first phase. Researchers set the minimal efficacy hypothesis at 55% event-free progression-free survival at 4 months, and a progression-free survival of 40% was predetermined to represent ineffectiveness.

There were 230 adverse events reported among 59 patients throughout the study. Grade 3 or higher adverse events represented 22.6% of all adverse events. There were seven grade 4 adverse events, and five grade 5 adverse events. Respiratory failure, which was defined as a severe adverse event, occurred in 18 patients.

Disclosure: For a full list of author disclosures, visit

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.